134 related articles for article (PubMed ID: 12959293)
1. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.
Sundberg S; Scheinin M; Illi A; Akkila J; Gordin A; Keränen T
Br J Clin Pharmacol; 1993 Nov; 36(5):451-6. PubMed ID: 12959293
[TBL] [Abstract][Full Text] [Related]
2. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise.
Illi A; Sundberg S; Koulu M; Scheinin M; Heinävaara S; Gordin A
Int J Clin Pharmacol Ther; 1994 Nov; 32(11):582-8. PubMed ID: 7874370
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
4. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.
Sundberg S; Scheinin M; Ojala-Karlsson P; Akkila J; Gordin A
Eur J Clin Pharmacol; 1993; 44(3):287-90. PubMed ID: 8491246
[TBL] [Abstract][Full Text] [Related]
5. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.
Sundberg S; Scheinin M; Ojala-Karlsson P; Kaakkola S; Akkila J; Gordin A
Clin Pharmacol Ther; 1990 Oct; 48(4):356-64. PubMed ID: 2225697
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Eur J Clin Pharmacol; 1996; 51(3-4):273-6. PubMed ID: 9010698
[TBL] [Abstract][Full Text] [Related]
7. Extraneuronal enzymatic degradation of myocardial interstitial norepinephrine in the ischemic region.
Fujii T; Yamazaki T; Akiyama T; Sano S; Mori H
Cardiovasc Res; 2004 Oct; 64(1):125-31. PubMed ID: 15364620
[TBL] [Abstract][Full Text] [Related]
8. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
Myllylä VV; Sotaniemi KA; Illi A; Suominen K; Keränen T
Eur J Clin Pharmacol; 1993; 45(5):419-23. PubMed ID: 8112370
[TBL] [Abstract][Full Text] [Related]
9. The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Gordin A; Kultalahti ER; Teräväinen H; Sovijärvi A
Parkinsonism Relat Disord; 2002 Jun; 8(5):349-55. PubMed ID: 15177064
[TBL] [Abstract][Full Text] [Related]
10. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
Keränen T; Gordin A; Harjola VP; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Seppälä L; Wikberg T
Clin Neuropharmacol; 1993 Apr; 16(2):145-56. PubMed ID: 8477410
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
12. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.
Keränen T; Gordin A; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Schultz E; Seppälä L; Wikberg T
Eur J Clin Pharmacol; 1994; 46(2):151-7. PubMed ID: 8039535
[TBL] [Abstract][Full Text] [Related]
14. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.
Illi A; Sundberg S; Ojala-Karlsson P; Korhonen P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1995 Aug; 58(2):221-7. PubMed ID: 7648772
[TBL] [Abstract][Full Text] [Related]
15. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
16. COMT inhibition with nitecapone does not affect the tyramine pressor response.
Sundberg S; Gordin A
Br J Clin Pharmacol; 1991 Jul; 32(1):130-2. PubMed ID: 1888633
[TBL] [Abstract][Full Text] [Related]
17. In vivo assessment of catechol O-methyltransferase activity in rabbit skeletal muscle.
Fujii T; Yamazaki T; Akiyama T; Sano S; Mori H
Auton Neurosci; 2004 Apr; 111(2):140-3. PubMed ID: 15182744
[TBL] [Abstract][Full Text] [Related]
18. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
19. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.
Li LS; Liu CZ; Xu JD; Zheng LF; Feng XY; Zhang Y; Zhu JX
World J Gastroenterol; 2015 Mar; 21(12):3509-18. PubMed ID: 25834315
[TBL] [Abstract][Full Text] [Related]
20. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.
Keränen T; Gordin A; Koulu M; Scheinin M; Antila S; Sundberg S; Wikberg T
J Neural Transm (Vienna); 1996; 103(6):729-36. PubMed ID: 8836934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
